The Medicines and Healthcare products Regulatory Agency has approved Foundayo, a weight-loss medication manufactured by Eli Lilly, marking the first European approval of the drug. The medication, also known as orforglipron, is available for private prescription purchase in the UK and represents another entry in the class of GLP-1 drugs designed to suppress appetite.
While the regulatory approval enables immediate use through the NHS for type 2 diabetes treatment, broader availability as a weight-loss option will require a separate application to the National Institute for Health and Care Excellence in England. The approval comes several months after the MHRA authorized a tablet version of Wegovy, a competing weight-loss medication.
Experts highlighted several potential advantages of Foundayo. Researchers noted that despite producing less dramatic weight-loss results compared to some alternative treatments, patients should still experience substantial clinical improvements in weight reduction. The medication is expected to be more affordable than other available weight-loss options, which the NHS has historically restricted due to cost considerations. Additionally, the pill can be taken at any time during the day, whereas the Wegovy tablet requires administration on an empty stomach, potentially improving convenience for patients.
Trial data indicated potential value for individuals transitioning away from weight-loss injections. Patients who had previously used injectable GLP-1 medications and subsequently took the daily tablet maintained their weight loss over a one-year period, addressing the documented risk of weight regain following discontinuation of injection-based treatments.
Medical professionals cautioned that Foundayo users should maintain complementary lifestyle modifications including balanced nutrition and regular physical activity. The medication can produce adverse effects such as nausea, diarrhea, constipation, and vomiting, consistent with other drugs in its category.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI